
==== Front
Eur J Epidemiol
Eur J Epidemiol
European Journal of Epidemiology
0393-2990
1573-7284
Springer Netherlands Dordrecht

39009924
1141
10.1007/s10654-024-01141-5
Mendelian Randomization
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
http://orcid.org/0000-0002-4387-386X
Yang Guoyi yanggy@connect.hku.hk

12
Mason Amy M. 34
Gill Dipender 5
Schooling C. Mary 16
http://orcid.org/0000-0001-5365-8760
Burgess Stephen sb452@medschl.cam.ac.uk

23
1 https://ror.org/02zhqgq86 grid.194645.b 0000 0001 2174 2757 School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
2 grid.5335.0 0000000121885934 MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
3 https://ror.org/013meh722 grid.5335.0 0000 0001 2188 5934 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
4 https://ror.org/013meh722 grid.5335.0 0000 0001 2188 5934 Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK
5 https://ror.org/041kmwe10 grid.7445.2 0000 0001 2113 8111 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
6 https://ror.org/00453a208 grid.212340.6 0000 0001 2298 5718 Graduate School of Public Health and Health Policy, City University of New York, New York City, NY USA
15 7 2024
15 7 2024
2024
39 8 857867
14 3 2024
5 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Plasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. Different plasma LDL-cholesterol lowering pathways may have distinct effects on biliary cholesterol and thereby gallstone disease risk. We conducted a Mendelian randomization (MR) study using data from the UK Biobank (30,547 gallstone disease cases/336,742 controls), FinnGen (34,461 cases/301,383 controls) and Biobank Japan (9,305 cases/168,253 controls). We first performed drug-target MR analyses substantiated by colocalization to investigate the effects of plasma LDL-cholesterol lowering therapies on gallstone disease risk. We then performed clustered MR analyses and pathway analyses to identify distinct mechanisms underlying the association of plasma LDL-cholesterol with gallstone disease risk. For a 1-standard deviation reduction in plasma LDL-cholesterol, genetic mimics of statins were associated with lower gallstone disease risk (odds ratio 0.72 [95% confidence interval 0.62, 0.83]), but genetic mimics of PCSK9 inhibitors and targeting apolipoprotein B were associated with higher risk (1.11 [1.03, 1.19] and 1.23 [1.13, 1.35]). The association for statins was supported by colocalization (posterior probability 98.7%). Clustered MR analyses identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease risk, with some evidence for ancestry-and sex-specific associations. Among variants lowering plasma LDL-cholesterol, those associated with lower gallstone disease risk were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters. This MR study provides genetic evidence that different plasma LDL-cholesterol lowering pathways have opposing effects on gallstone disease risk.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10654-024-01141-5.

Keywords

LDL-cholesterol
Gallstone disease
Drug-target Mendelian randomization
Clustered Mendelian randomization
Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant 116074 Mason Amy M. British Heart Foundation Centre of Research Excellence RE/18/4/34215 Gill Dipender http://dx.doi.org/10.13039/100010269 Wellcome Trust 225790/Z/22/Z Burgess Stephen Innovation Medical Research Council MC_UU_00002/7 Burgess Stephen http://dx.doi.org/10.13039/501100000274 British Heart Foundation RG/13/13/30194; RG/18/13/33946 BHF Cambridge CRERE/18/1/34212 National Institute for Health Research Cambridge Biomedical Research Centre NIHR203312 http://dx.doi.org/10.13039/501100023699 Health Data Research UK Health Data Research UK issue-copyright-statement© Pietro Paolo Sanna 2024
==== Body
pmcIntroduction

Plasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease (CAD) risk [1], whereas biliary cholesterol promotes cholesterol gallstones formation [2]. A recent randomized controlled trial (RCT) showed lowering plasma LDL-cholesterol with bempedoic acid, an adenosine triphosphate (ATP) citrate lyase inhibitor, increased risk of gallstones [3], but trial evidence for other lipid modifiers is limited [4]. Therefore, it remains unclear whether the lithogenic effect is a general consequence of lowering plasma LDL-cholesterol or is unique to bempedoic acid.

RCTs are not usually designed or powered to identify adverse effects or novel indications. Observational studies suggest statin use is associated with lower gallstone disease risk [5, 6], but these studies could be biased due to residual confounding or selection bias. Mendelian randomization (MR), an instrumental variable analysis with genetic instruments, is more robust to confounding than conventional observational studies [7]. However, previous MR studies have yielded contradictory results, suggesting a positive [8, 9] or null [10] association of lower plasma LDL-cholesterol with gallstone disease risk. Genetic studies of specific gene regions did not show a uniform association of lower plasma LDL-cholesterol with gallstone disease risk [9–13]. Nevertheless, the possibility of systematic differences in the lithogenic effects of different plasma LDL-cholesterol lowering pathways has less often been considered.

Plasma LDL-cholesterol is regulated by different biological pathways [14], which could have distinct effects on biliary cholesterol and thereby gallstone disease. For example, statins reduce plasma LDL-cholesterol by inhibiting cholesterol biosynthesis [15], which may decrease biliary cholesterol [16] and reduce gallstone disease risk. However, pathways reducing plasma LDL-cholesterol while elevating biliary cholesterol, such as activating adenosine triphosphate (ATP)-binding cassette transporters G5/8 (ABCG5/8), may increase gallstone disease risk [11].

We hypothesized that different plasma LDL-cholesterol lowering pathways have distinct effects on risk of gallstone disease. First, we used MR to assess the associations of genetic mimics of current and emerging plasma LDL-cholesterol lowering therapies with gallstone disease risk. Second, we investigated distinct pathways underlying the association of plasma LDL-cholesterol with gallstone disease risk. Where possible, we assessed ancestry- and sex-specific associations, because gallstone prevalence is higher in European than Asian ancestry individuals, and in women than men [2].

Methods

Study design

We used individual-level data from UK Biobank [17] and summary-level data from FinnGen [18] and Biobank Japan [19] for gallstone disease. We selected genetic mimics of plasma LDL-cholesterol lowering therapies from genes encoding the molecular target of each therapy. We conducted drug-target MR analyses to assess the associations of genetic mimics of each therapy with gallstone disease risk. We performed colocalization analyses to examine whether any associations found were driven by a shared causal variant between exposure and outcome or were confounded by linkage disequilibrium [20].

We extracted genetic predictors for plasma LDL-cholesterol from across the genome. We conducted clustered MR analyses to identify distinct clusters of genetic variants having similar causal estimates for plasma LDL-cholesterol on gallstone disease risk [21]. We performed pathway analyses to investigate biological pathways relating to each cluster. A summary of the study design is shown in eFig.1 (Online resource).

Data sources

The UK Biobank recruited approximately 500,000 people (intended age 40–69 years, 94% self-reported European ancestry) between 2006 and 2010 from across the United Kingdom [17]. Individual-level data used were under application 98032 (October 2021 updated). Cases were defined based on self-reported history of gallstones, International Classification of Diseases (ICD)-9 and ICD-10 codes related to gallstones, and medical treatment of gallstones (Online resource: eTable 1), as previously [22]. Both prevalent and incident cases were included. Controls were individuals without gallstone-related disease or treatment. Individuals who underwent cholecystectomy due to an alternative pathology (e.g., neoplasm) were excluded. We included 367,289 unrelated individuals of European ancestry (30,547 gallstone disease cases and 336,742 controls) with genomic data passing quality control as described previously [23]. We used logistic regression to obtain sex-combined and sex-specific genetic associations with gallstone disease.

Summary-level data from FinnGen (R8 release) included 34,461 gallstone cases and 301,383 controls (mean age 52 years, 55.7% women) [18]. Cases were defined based on ICD-8, 9, 10 codes [18]. Summary-level data from Biobank Japan included 9,305 gallstone cases and 168,253 controls (mean age 63 years, 46.3% women) [19]. Cases were defined based on ICD-10 codes [19]. Definitive codes of gallstone disease are provided in eTable 1 (Online resource).

Genetic instruments

We selected genetic instruments based on their associations with plasma LDL-cholesterol obtained from ancestry-specific summary-level data from the Global Lipids Genetics Consortium (GLGC) (1,231,289/82,587 people of European/East Asian ancestry) [24], but not based on functional information. We selected genetic mimics of plasma LDL-cholesterol lowering therapies from genes encoding the molecular targets of each therapy (i.e., HMGCR for statins, PCSK9 for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, NPC1L1 for ezetimibe, ACLY for ATP citrate lyase inhibitors, LDLR for targeting LDL receptors, and APOB for targeting apolipoprotein B (apoB)), as previously [25, 26]. We used genetic mimics of targeting ABCG5/8 from ABCG5/8 as a positive control exposure, because ABCG5/8 is a well-established lithogenic gene [2]. We included all variants within 100 kb on either side of each target gene that were in low linkage disequilibrium (r2 < 0.1) and were genome-wide significantly (p value < 5 × 10− 8) associated with plasma LDL-cholesterol. We used a less stringent cut-off for linkage disequilibrium (r2 < 0.1) to obtain more variants in each gene region to increase the power [27]. We also extracted genetic predictors for plasma LDL-cholesterol from across the genome that were uncorrelated (r2 < 0.001) and genome-wide significantly (p value < 5 × 10− 8) associated with plasma LDL-cholesterol. Estimates were expressed in 1-standard deviation (around 0.87 mmol/L) reduction in plasma LDL-cholesterol.

We used the F-statistic to assess instrument strength, approximated by the square of each SNP-exposure association divided by the square of its standard error [28]. We used PhenoScanner, a database of genotype-phenotype associations [29, 30], to check whether SNPs were genome-wide significantly (p value < 5 × 10− 8) associated with common confounders (i.e., socioeconomic status, smoking, alcohol drinking and physical activity). We included these SNPs in the main analysis, and excluded them in the sensitivity analysis. We also used positive control outcomes, i.e., CAD from Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) Consortium (60,801 cases and 123,504 controls) [31] for people of European ancestry and myocardial infarction (MI) from Biobank Japan (14,992 cases and 146,214 controls) [19] for East Asians. A summary of genome-wide association studies (GWAS) used is provided in eTable 2 (Online resource).

MR analysis

We aligned SNPs based on alleles and allele frequencies. We used proxy SNPs (r2 ≥ 0.8), where possible, when SNPs were not available in the outcome GWAS. We used the 1000 Genomes reference panel to obtain linkage disequilibrium. We selected a European population for proxy SNPs in the UK Biobank and FinnGen, and an East Asian population for proxy SNPs in Biobank Japan. We calculated MR estimates by meta-analyzing Wald estimates (the ratio of the genetic association with outcome to the genetic association with exposure) using inverse variance weighting (IVW) with fixed effects for three SNPs or fewer and random effects for four SNPs or more [32]. To assess the robustness of the IVW estimates, we conducted sensitivity analyses using weighted median [33] and MR Egger [34]. We used the MR Egger intercept to assess directional pleiotropy [34]. For uncorrelated SNPs (r2 < 0.001), we used IVW [32] and MR Egger [34] assuming independent genetic instruments. For SNPs in low linkage disequilibrium (r2 < 0.1), we used IVW [27] and MR Egger [35] extended to account for correlations between genetic instruments by fitting a generalized weighted linear regression model using a weighting matrix.

We meta-analyzed MR estimates from the three biobanks using a fixed-effects model unless the Q-statistic suggested heterogeneity when we used a random-effects model. We assessed differences by sex using a two-sided z-test [36].

Colocalization analysis

We performed colocalization analyses in a Bayesian framework to assess whether any associations found in drug-target MR were driven by a shared causal variant between plasma LDL-cholesterol and gallstone disease or were confounded by linkage disequilibrium [20]. This method uses Approximate Bayes Factor computations to assess the posterior probability of several hypotheses [20]. H0, no association with either trait; H1, association with plasma LDL-cholesterol only; H2, association with gallstone disease only; H3, associations of two independent variants and one for each trait; H4, associations of one shared variant with both traits [20]. A probability of H4 larger than 0.80 provides evidence for colocalization [20]. We included variants (minor allele frequency > 0.1%) in or near (+/-100 kb) the target gene where any associations were identified. We set the prior probabilities as recommended, i.e., 1.0e-4 for a variant associated with plasma LDL-cholesterol, 1.0e-4 for a variant associated with gallstone disease, and 1.0e-5 for a variant associated with both traits [20]. We also calculated the posterior probability for a shared variant associated with both traits conditional on the presence of a variant associated with gallstone disease, as the power to detect colocalization is low when the variants are not strongly associated with the outcome [37].

Clustered MR

We used the MR-Clust method to identify distinct clusters of genetic variants having similar causal estimates for plasma LDL-cholesterol on gallstone disease, which might reflect distinct biological pathways [21]. The MR-Clust accounts for differential uncertainty in the causal estimates, and includes a null cluster where SNP-specific estimates are centred around zero and a junk cluster where SNP-specific estimates are highly dispersed and are considered outliers [21]. The presence of null and junk clusters requires substantial evidence of similarity to define a cluster, which avoids the detection of spurious clusters [21]. We only included variants with inclusion probability > 0.80 in each cluster, and only reported a cluster if at least four variants satisfy this criterion, as recommended [21].

Pathway analysis

We performed pathway analysis to examine biological pathways relating to each variant cluster using the Functional Mapping and Annotation (FUMA) platform, which includes SNP2GENE and GENE2FUNC functions [38]. We first applied the SNP2GENE function to map cluster-specific genetic variants to genes, where we used 100-kb positional mapping and expression quantitative trait locus (eQTL) mapping based on GTEx v8 [38]. We then used the GENE2FUNC function to associate the mapped genes with biological pathways defined by KEGG and Reactome database [38].

All statistical analyses were conducted using R version 4.2.1 and the packages “ieugwasr”, “TwoSampleMR”, “MendelianRandomization”, “metafor”, “coloc”, and “mrclust”.

Results

Baseline characteristics of UK Biobank participants

Baseline characteristics of 367,289 UK Biobank participants (cases = 21,201 women/9,346 men, controls = 177,478 women/159,264 men) included in this study are shown in Table 1. Cases were older at baseline (mean age 59.4 vs. 57.0 years) and had higher body mass index (mean 29.6 vs. 27.2 kg/m2) than controls. Cases had a greater proportion of women (69.4% vs. 52.7%) and current lipid-lowering medication users (22.1% vs. 16.5%) but had a smaller proportion of current alcohol drinkers (89.1% vs. 93.6%) than controls.

Table 1 Baseline characteristics of gallstone disease cases and controls in the UK Biobank

Characteristics	Cases (N = 30,547)	Controls (N = 336,742)	
Age at recruitment, years	59.4 (7.4)	57.0 (8.0)	
Sex			
 Men	9,346 (30.6)	159,264 (47.3)	
 Women	21,201 (69.4)	177,478 (52.7)	
LDL-cholesterol, mmol/L	3.5 (0.9)	3.6 (0.9)	
BMI, kg/m2	29.6 (5.5)	27.2 (4.6)	
SBP, mmHg	138.8 (18.4)	137.6 (18.6)	
Smoking			
 Current	3,118 (10.2)	34,712 (10.3)	
 Other	27,429 (89.8)	302,030 (89.7)	
Alcohol drinking			
 Current	27,204 (89.1)	315,226 (93.6)	
 Other	3,343 (10.9)	21,516 (6.4)	
Lipid-lowering medication			
 Current	6,751 (22.1)	55,467 (16.5)	
 Other	23,796 (77.9)	281,275 (83.5)	
BMI: body mass index; LDL: low-density lipoprotein; SBP: systolic blood pressure. Data are mean (standard deviation) for continuous variables or N (%) for categorical variables

Genetic instruments

We extracted SNPs for plasma LDL-cholesterol lowering therapies in people of European and East Asian ancestry, respectively (Online resource: eTable 3). We were unable to extract SNPs for ATP citrate lyase inhibitors in people of European or East Asian ancestry, or for ezetimibe and targeting ABCG5/8 in East Asians, because the SNPs in or near the target genes were not genome-wide significantly associated with plasma LDL-cholesterol (p values > 5 × 10− 8). We extracted 324 and 43 SNPs for plasma LDL-cholesterol in people of European and East Asian ancestry, respectively (Online resource: eTable 4).

The F-statistics for all SNPs were > 10. Variance in plasma LDL-cholesterol explained by SNPs for each therapy and plasma LDL-cholesterol is provided in eTable 5 (Online resource). None of the SNPs for each therapy were genome-wide significantly associated with common confounders (p values > 5 × 10− 8), but four SNPs for plasma LDL-cholesterol were associated with smoking or alcohol drinking (Online resource: eTable 6). We included these four SNPs in the main analysis and excluded them in the sensitivity analysis. As expected, SNPs for each therapy and lower plasma LDL-cholesterol were associated with lower risk of CAD and MI (Online resource: eFig.2–3).

Drug-target MR

After meta-analyzing MR estimates from the three biobanks, genetic mimics of statins were associated with lower gallstone disease risk, while genetic mimics of PCSK9 inhibitors, targeting apoB, and targeting ABCG5/8 were associated with higher gallstone disease risk (Fig. 1). Targeting LDL receptors had a similar IVW estimate as PCSK9 inhibitors, despite the p value of 0.06 (Fig. 1). We did not observe heterogeneity in IVW estimates across biobanks (p values for heterogeneity > 0.05). The weighted median and MR Egger gave similar interpretations, although the MR Egger intercept indicated possible directional pleiotropy for ezetimibe (UK Biobank) and PCSK9 inhibitors (FinnGen) (Fig. 1). For a 1-standard deviation reduction in plasma LDL-cholesterol, associations for statins (odds ratio for women 0.76 [95% confidence interval 0.58, 1.00] vs. men 0.99 [0.62 to 1.58]), PCSK9 inhibitors (women 1.09 [0.95 to 1.26] vs. men 1.36 [1.11 to 1.67]) and targeting ABCG5/8 (women 243.40 [114.10 to 519.26] vs. men 58.39 [29.94 to 113.86]) slightly differed by sex (Online resource: eFig.4, p values for sex differences 0.332, 0.081 and 0.006).

Fig. 1 Mendelian randomization estimates for genetic mimics of plasma LDL-cholesterol lowering therapies on risk of gallstone disease

ABCG5/8, adenosine triphosphate (ATP)-binding cassette transporters G5/8; ApoB, apolipoprotein B; IVW, inverse variance weighted; LDL, low-density lipoprotein; PCSK9, proprotein convertase subtilisin/kexin type 9. Estimates are expressed in odds ratio per 1-standard deviation (around 0.87 mmol/L) reduction in plasma LDL-cholesterol. * denotes p value < 0.05; ** denotes p value < 0.001. P values (MR Egger intercept) for statins, PCSK9 inhibitors, ezetimibe, targeting LDL receptors, targeting apoB, and targeting ABCG5/8 were 0.98, 0.33, 0.002, 0.81, 0.21, and 0.18 in the UK Biobank, 0.53, 0.03, 0.98, 0.60, 0.43, and 0.16 in FinnGen, and 0.57, 0.60, NA, 0.52, 0.31, and NA in Biobank Japan

Colocalization analysis

Colocalization analyses were performed for plasma LDL-cholesterol with gallstone disease in or near (+-100kb) HMGCR, PCSK9, APOB, and ABCG5/8 using the UK Biobank and FinnGen. The posterior probability for a shared variant associated with both traits was 98.7% for the HMGCR gene region but < 10% for the other gene regions (Fig. 2). At the HMGCR gene region, conditional on the existence of a shared variant associated with both traits, rs12916 was the shared variant with posterior probability > 99.9%. The posterior probability for a variant associated with plasma LDL-cholesterol only was > 50% for the PCSK9 and APOB gene regions; the posterior probability for independent variants associated with each trait was > 99.9% for the ABCG5/8 gene region (Online resource: eTable 7).

Fig. 2 Colocalization analyses for plasma LDL-cholesterol with gallstone disease in or near (+-100 kb) the target gene of each therapy

ABCG5/8: adenosine triphosphate (ATP)-binding cassette transporters G5/8; ApoB: apolipoprotein B; LDL: low-density lipoprotein; PCSK9: proprotein convertase subtilisin/kexin type 9. Prior probabilities were set to 1.0e-4 for a variant associated with plasma LDL-cholesterol, 1.0e-4 for a variant associated with gallstone disease, and 1.0e-5 for a variant associated with both traits. Probability for colocalization means the posterior probability for a shared variant associated with both traits; conditional probability means the posterior probability for a shared variant associated with both traits conditional on the presence of a variant associated with gallstone disease. Conditioning on the existence of a shared variant associated with both traits, the variant highlighted with a label has the largest posterior probability to be the shared variant

Clustered MR

Using all SNPs for lower plasma LDL-cholesterol, there was a positive association with gallstone disease risk in the UK Biobank and FinnGen but a null association in Biobank Japan (Fig. 3). However, we observed heterogeneity in SNP-specific estimates (p values for heterogeneity < 0.001). Clustered MR analyses consistently identified variant clusters showing opposing associations of lower plasma LDL-cholesterol with gallstone disease risk (Figs. 3 and 4). The MR Egger intercept indicated possible directional pleiotropy for cluster 2 (UK Biobank), cluster 2 and 4 (FinnGen), and cluster 1 and 2 (Biobank Japan); however, the weighted median and MR Egger estimates were in the same direction as the IVW estimates (Fig. 3). By contrast, these clusters were generally associated with lower risk of CAD and MI (Online resource: eFig.3). Sensitivity analysis excluding SNPs associated with smoking or alcohol drinking did not change the results substantially (Online resource: eFig.5–6).

Cluster patterns were consistent in the UK Biobank and FinnGen (Figs. 3 and 4), with overlapping cluster-specific SNPs (Online resource: eTable 8) and similar SNP-specific estimates (Online resource: eFig.7). Sex-specific clustered MR analyses also showed such opposing associations, but the pattern appeared more evident in women than men (Online resource: eFig.8–9).

Fig. 3 Mendelian randomization estimates for genetically predicted lower plasma LDL-cholesterol on risk of gallstone disease using all SNPs and cluster-specific SNPs (inclusion probability > 0.80)

IVW: inverse variance weighted; LDL: low-density lipoprotein. Estimates are expressed in odds ratio per 1-standard deviation (around 0.87 mmol/L) reduction in plasma LDL-cholesterol. * denotes p value < 0.05; ** denotes p value < 0.001. P values (MR Egger intercept) for all SNPs, cluster 1, cluster 2, cluster 3, cluster 4, and cluster 5 were 0.19, 0.07, 0.01, 0.78, 0.22, and 0.76 in the UK Biobank, 0.70, 0.88, 0.001, 0.65, < 0.001, and 0.97 in FinnGen, and 0.38, 0.04, 0.01, NA, NA, and NA in Biobank Japan

Fig. 4 Genetic associations with plasma LDL-cholesterol reduction (standard deviation) and risk of gallstone disease (log odds) for SNPs with inclusion probability > 0.80 in clustered Mendelian randomization analyses

LDL: low-density lipoprotein. Points represent SNPs; dotted lines are cluster means; error bars are 95% confidence intervals for genetic associations. A positive slope indicates an association of lower plasma LDL-cholesterol with higher risk of gallstone disease; a negative slope indicates an association of lower plasma LDL-cholesterol with lower risk of gallstone disease

Pathway analysis

We found clusters 2 and 3 in FinnGen, cluster 3 in the UK Biobank, and cluster 2 in Biobank Japan mapped to specific pathways (Online resource: eTable 9). Cluster 2 in FinnGen showing an inverse association of lower plasma LDL-cholesterol with gallstone disease was mapped to glycosphingolipid biosynthesis pathway, while other clusters showing a positive association were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters.

Discussion

This multi-biobank MR study including 880,691 individuals (74,313 gallstone disease cases) provides genetic evidence that statins may reduce gallstone disease risk, consistent with previous observational studies [5, 6]. Our investigation has added to the evidence base by identifying distinct and opposing pathways underlying the association of plasma LDL-cholesterol with gallstone disease.

Genetic evidence suggested statins may reduce the risk of gallstone disease, while PCSK9 inhibitors, targeting apoB and targeting ABCG5/8 may increase the risk. These findings are consistent with observational studies showing long-term use of statins is associated with lower gallstone disease risk [5, 6], and a previous MR study showing ABCG5/8 variants lowering plasma LDL-cholesterol are associated with higher gallstone disease risk [11]. However, an RCT including 9,270 individuals with chronic kidney disease showed simvastatin plus ezetimibe did not affect gallstone risk during a follow-up of 4.9 years, when 216 individuals developed gallstones [4]. A previous genetic study including 63,051 individuals (3,323 with symptomatic gallstones) showed variants in PCSK9 or APOB were not associated with risk of symptomatic gallstone disease [10]. The small number of gallstone cases may have limited the detection of any possible effect in these studies. Meta-analyses of 21 RCTs showed statins reduced the risk of pancreatitis, a common complication of gallstone disease [39].

Plasma LDL-cholesterol lowering therapies may have distinct effects on biliary cholesterol and thereby gallstone disease. Statins decrease hepatic cholesterol synthesis [15], and may decrease biliary cholesterol [16] and facilitate cholesterol gallstone dissolution [40, 41]. PCSK9 inhibitors increase LDL receptors and targeting apoB decreases apoB-containing particles [15], which may increase hepatic and biliary cholesterol [2]. Activating ABCG5/8 facilitates cholesterol efflux into the intestine and the gallbladder, which increases biliary cholesterol [2]. Increased biliary cholesterol accelerates supersaturation of bile and promotes cholesterol gallstone formation [2].

Colocalization analysis substantiated the association of statins with gallstone disease. A lack of colocalization for PCSK9 inhibitors and targeting apoB is possibly due to insufficient power. However, colocalization analysis suggested the association of targeting ABCG5/8 with gallstone disease was confounded by linkage disequilibrium. This could be explained by different lead variants for plasma versus biliary cholesterol in or near ABCG5/8. ABCG5/8 increases cholesterol excretion into the intestine and the gallbladder and may have a larger effect on biliary cholesterol than plasma LDL-cholesterol. Such differences would also explain the implausibly high MR estimates for targeting ABCG5/8, which are presented in effect sizes of plasma LDL-cholesterol reduction.

Using all SNPs for lower plasma LDL-cholesterol, there was a positive or null association with gallstone disease, as shown in previous MR studies [8, 10]. However, we identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease. Among variants predicting lower plasma LDL-cholesterol, those associated with lower gallstone disease risk were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher gallstone disease risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters. These findings are consistent with the evidence available and the mechanisms of plasma LDL-cholesterol lowering therapies. In vitro studies have showed statins affect glycosphingolipid profiles through inhibiting Rab prenylation [42], which could suppress gallstone formation [43]. PCSK9 inhibitors and targeting apoB are involved in plasma LDL assembly and clearance, and ABCG5/8 are key members of ATP-binding cassette transporters [15]. Correspondingly, targeting apoB had similar MR estimates as cluster 3 in FinnGen and UK Biobank and cluster 2 in Biobank Japan; targeting ABCG5/8 had similar MR estimates as cluster 5 in FinnGen and UK Biobank (Figs. 1 and 3).

Unlike the atheroprotective effects, the lithogenic effects vary between different plasma LDL-cholesterol lowering pathways, which cast doubt on a causal role of plasma LDL-cholesterol in gallstone disease. Similarly, previous MR studies showed plasma LDL-cholesterol lowering therapies differed in their associations with body mass index [44] and type 2 diabetes [45]. These insights highlight the importance of pathway-specific investigations to identify novel indications for biomarkers, here specifically plasma LDL-cholesterol.

The opposing associations of plasma LDL-cholesterol with gallstone disease seemed more evident in European than East Asian ancestry individuals and in women than men, consistent with different gallstone prevalence rates by ancestry and sex [2]. Plasma LDL-cholesterol lowering therapies may have distinct effects on biliary cholesterol and thereby cholesterol gallstones; however, pigment gallstones are more common in East Asians than Europeans [46], which may explain the difference by ancestry. Statins partially operate through sex hormones [47], which could be relevant to the more marked association in women than men. Alternatively, statins decreasing calcium, another component of gallstones, specifically in women [48] might play a role.

This trans-ancestry study takes advantage of three large-scale biobanks. A systematic difference in the lithogenic effects of different plasma LDL-cholesterol lowering pathways is novel. This study has several limitations. First, MR relies on three rigorous assumptions, that is genetic instruments should be strongly related to the exposure, share no common cause with the outcome, and be independent of the outcome given the exposure [7]. We calculated the F-statistics, checked genetic associations with common confounders, and used CAD and MI as positive control outcomes to assess the validity of genetic instruments. Second, we were unable to assess the lithogenic effect of ATP citrate lyase inhibitors due to a lack of valid instruments. Although variants in the ACLY gene have been used in a prior Mendelian randomization analysis, none of these variants were associated with plasma LDL-cholesterol at even a suggestive level of genome-wide significance (p values > 10− 3 for all variants) [26]. Third, we performed colocalization analyses for plasma LDL-cholesterol with gallstone disease, while biliary cholesterol likely underlies any effects on gallstone disease. The discrepancy between plasma versus biliary cholesterol may partly explain some lack of colocalization. Replication using biliary cholesterol would be ideal when relevant GWAS becomes available. Fourth, not all the variant clusters could be mapped to specific pathways, possibly due to the small number of SNPs with inclusion probability > 0.80 in some clusters. However, such a conservative inclusion criterion avoids the generation of spurious clusters by chance [21]. Fifth, meta-analysis of MR estimates across the biobanks can be difficult to interpret, as they included individuals of different ancestries and can be open to different sources of bias. Gallstone disease studied here is not specific to cholesterol gallstones and the definitions slightly vary across the three biobanks; however, we still observed consistent patterns. Sixth, we did not take into account potential non-linearity, because a previous MR study suggested a linear association of plasma LDL-cholesterol with gallstone disease risk [9]. Finally, MR assesses lifelong effects, which cannot directly inform the quantitative effects of plasma LDL-cholesterol lowering therapies in the short term.

Conclusions

This genetic study supports that different plasma LDL-cholesterol lowering pathways have opposing effects on risk of gallstone disease. Specifically, statins may decrease the risk of gallstone disease but PCSK9 inhibitors and targeting apoB may increase the risk. Plasma LDL-cholesterol lowering through glycosphingolipid biosynthesis pathway may decrease the risk of gallstone disease but through pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters may increase the risk.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Abbreviations

ABCG5/8 Adenosine triphosphate-binding cassette transporters G5/8

ApoB Apolipoprotein B

ATP Adenosine triphosphate

CAD Coronary artery disease

CARDIoGRAMplusC4D Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics

eQTL Expression quantitative trait locus

FUMA Functional Mapping and Annotation

GLGC Global Lipids Genetics Consortium

GWAS Genome-wide association studies

ICD International Classification of Diseases

IVW Inverse variance weighting

LDL Low-density lipoprotein

MI Myocardial infarction

MR Mendelian randomization

PCSK9 Proprotein convertase subtilisin/kexin type 9

RCT Randomized controlled trial

Acknowledgements

The authors acknowledge the UK Biobank for approving our application, and GLGC, FinnGen, Biobank Japan, and CARDIoGRAMplusC4D Consortium for their publicly available summary data.

Author contributions

GY and SB designed the study. GY undertook analyses with feedback from AMM, DG, CMS and SB. GY drafted the manuscript with critical feedback and revisions from AMM, DG, CMS and SB. GY is the guarantor of this work and takes responsibility for the integrity of the data analysis. All authors read and approved the final version of the manuscript.

Funding

GY is supported by the Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship from the University of Hong Kong. AMM is funded by the EU/EFPIA Innovative Medicines Initiative Joint Undertaking BigData@Heart grant 116074. DG is supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College. SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). This research was supported by British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge CRE (RE/18/1/34212), and the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR203312). This research was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The funders had no role in the study design, analyses, or interpretation of results. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Data availability

This study has been conducted using the UK Biobank Resource under Application number 98032. Summary-level data analyzed are available in the website http://csg.sph.umich.edu/willer/public/glgc-lipids2021/ for GLGC, https://www.finngen.fi/en/access_results for FinnGen, https://pheweb.jp/downloads for Biobank Japan, and http://www.cardiogramplusc4d.org/data-downloads/ for CARDIoGRAMplusC4D Consortium. The R code for data analysis is shared in the GitHub https://github.com/YANGGYEMMA/LDL_and_gallstones.

Declarations

Ethics approval

This study has been conducted using the UK Biobank Resource (Application number 98032). The UK Biobank obtained ethical approval from the North West Multi-centre Research Ethics Committee. The analysis of publicly available summary statistics does not require ethical approval.

Consent to participate

The UK Biobank participants provided written informed consent. Participants of the original studies of publicly available summary statistics also provided informed consent.

Competing interests

The authors declared no conflict of interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Ference BA Ginsberg HN Graham I Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur Heart J 2017 38 32 2459 72 10.1093/eurheartj/ehx144 28444290
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. 10.1093/eurheartj/ehx14428444290
2. Lammert F Gurusamy K Ko CW Gallstones Nat Reviews Disease Primers 2016 2 16024 10.1038/nrdp.2016.24 27121416
Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024. 10.1038/nrdp.2016.2427121416
3. Nissen SE Lincoff AM Brennan D Bempedoic Acid and Cardiovascular outcomes in statin-intolerant patients N Engl J Med 2023 388 15 1353 64 10.1056/NEJMoa2215024 36876740
Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. 10.1056/NEJMoa221502436876740
4. Baigent C Landray MJ Reith C The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet (London England) 2011 377 9784 2181 92 10.1016/s0140-6736(11)60739-3 21663949
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet (London England). 2011;377(9784):2181–92. 10.1016/s0140-6736(11)60739-321663949
5. Bodmer M Brauchli YB Krähenbühl S Jick SS Meier CR Statin use and risk of gallstone disease followed by cholecystectomy JAMA 2009 302 18 2001 7 10.1001/jama.2009.1601 19903921
Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302(18):2001–7. 10.1001/jama.2009.160119903921
6. Erichsen R Frøslev T Lash TL Pedersen L Sørensen HT Long-term statin use and the risk of gallstone disease: a population-based case-control study Am J Epidemiol 2011 173 2 162 70 10.1093/aje/kwq361 21084557
Erichsen R, Frøslev T, Lash TL, Pedersen L, Sørensen HT. Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol. 2011;173(2):162–70. 10.1093/aje/kwq36121084557
7. Lawlor DA Harbord RM Sterne JA Timpson N Davey Smith G Mendelian randomization: using genes as instruments for making causal inferences in epidemiology Stat Med 2008 27 8 1133 63 10.1002/sim.3034 17886233
Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–63. 10.1002/sim.303417886233
8. Chen L Yang H Li H He C Yang L Lv G Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study Hepatology (Baltimore MD) 2022 75 4 785 96 10.1002/hep.32183 34624136
Chen L, Yang H, Li H, He C, Yang L, Lv G. Insights into modifiable risk factors of cholelithiasis: a Mendelian randomization study. Hepatology (Baltimore MD). 2022;75(4):785–96. 10.1002/hep.3218334624136
9. Chen L Qiu W Sun X Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis Gut 2024 73 3 521 32 10.1136/gutjnl-2023-330784 37945330
Chen L, Qiu W, Sun X, et al. Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis. Gut. 2024;73(3):521–32. 10.1136/gutjnl-2023-33078437945330
10. Stender S Frikke-Schmidt R Benn M Nordestgaard BG Tybjærg-Hansen A Low-density lipoprotein cholesterol and risk of gallstone disease: a Mendelian randomization study and meta-analyses J Hepatol 2013 58 1 126 33 10.1016/j.jhep.2012.08.013 22922093
Stender S, Frikke-Schmidt R, Benn M, Nordestgaard BG, Tybjærg-Hansen A. Low-density lipoprotein cholesterol and risk of gallstone disease: a Mendelian randomization study and meta-analyses. J Hepatol. 2013;58(1):126–33. 10.1016/j.jhep.2012.08.01322922093
11. Stender S Frikke-Schmidt R Nordestgaard BG Tybjærg-Hansen A The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease J Am Coll Cardiol 2014 63 20 2121 8 10.1016/j.jacc.2013.12.055 24657701
Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. The ABCG5/8 cholesterol transporter and myocardial infarction versus gallstone disease. J Am Coll Cardiol. 2014;63(20):2121–8. 10.1016/j.jacc.2013.12.05524657701
12. Lauridsen BK Stender S Frikke-Schmidt R Nordestgaard BG Tybjærg-Hansen A Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease Eur Heart J 2015 36 25 1601 8 10.1093/eurheartj/ehv108 25841872
Lauridsen BK, Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. Eur Heart J. 2015;36(25):1601–8. 10.1093/eurheartj/ehv10825841872
13. Qayyum F Lauridsen BK Frikke-Schmidt R Kofoed KF Nordestgaard BG Tybjærg-Hansen A Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease Eur Heart J 2018 39 22 2106 16 10.1093/eurheartj/ehy068 29529257
Qayyum F, Lauridsen BK, Frikke-Schmidt R, Kofoed KF, Nordestgaard BG, Tybjærg-Hansen A. Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease. Eur Heart J. 2018;39(22):2106–16. 10.1093/eurheartj/ehy06829529257
14. Luo J Yang H Song BL Mechanisms and regulation of cholesterol homeostasis Nat Rev Mol Cell Biol 2020 21 4 225 45 10.1038/s41580-019-0190-7 31848472
Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–45. 10.1038/s41580-019-0190-731848472
15. Ray KK Corral P Morales E Nicholls SJ Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options Lancet (London England) 2019 394 10199 697 708 10.1016/s0140-6736(19)31950-6 31448741
Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet (London England). 2019;394(10199):697–708. 10.1016/s0140-6736(19)31950-631448741
16. Ahmed O Littmann K Gustafsson U Ezetimibe in Combination with Simvastatin reduces remnant cholesterol without affecting biliary lipid concentrations in gallstone patients J Am Heart Association 2018 7 24 e009876 10.1161/jaha.118.009876
Ahmed O, Littmann K, Gustafsson U, et al. Ezetimibe in combination with simvastatin reduces remnant cholesterol without affecting biliary lipid concentrations in gallstone patients. J Am Heart Association. 2018;7(24):e009876. 10.1161/jaha.118.009876
17. Bycroft C Freeman C Petkova D The UK Biobank resource with deep phenotyping and genomic data Nature 2018 562 7726 203 9 10.1038/s41586-018-0579-z 30305743
Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9. 10.1038/s41586-018-0579-z30305743
18. Kurki MI Karjalainen J Palta P FinnGen provides genetic insights from a well-phenotyped isolated population Nature 2023 613 7944 508 18 10.1038/s41586-022-05473-8 36653562
Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508–18. 10.1038/s41586-022-05473-836653562
19. Sakaue S Kanai M Tanigawa Y A cross-population atlas of genetic associations for 220 human phenotypes Nat Genet 2021 53 10 1415 24 10.1038/s41588-021-00931-x 34594039
Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415–24. 10.1038/s41588-021-00931-x34594039
20. Giambartolomei C Vukcevic D Schadt EE Bayesian test for colocalisation between pairs of genetic association studies using summary statistics PLoS Genet 2014 10 5 e1004383 10.1371/journal.pgen.1004383 24830394
Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383. 10.1371/journal.pgen.100438324830394
21. Foley CN Mason AM Kirk PDW Burgess S MR-Clust: clustering of genetic variants in Mendelian randomization with similar causal estimates Bioinf (Oxford England) 2021 37 4 531 41 10.1093/bioinformatics/btaa778
Foley CN, Mason AM, Kirk PDW, Burgess S. MR-clust: clustering of genetic variants in Mendelian randomization with similar causal estimates. Bioinf (Oxford England). 2021;37(4):531–41. 10.1093/bioinformatics/btaa778
22. Fairfield CJ Drake TM Pius R Genome-wide analysis identifies gallstone-susceptibility loci including genes regulating gastrointestinal motility Hepatology (Baltimore MD) 2022 75 5 1081 94 10.1002/hep.32199 34651315
Fairfield CJ, Drake TM, Pius R, et al. Genome-wide analysis identifies gallstone-susceptibility loci including genes regulating gastrointestinal motility. Hepatology (Baltimore MD). 2022;75(5):1081–94. 10.1002/hep.3219934651315
23. Astle WJ Elding H Jiang T The allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease Cell 2016 167 5 1415 e2919 10.1016/j.cell.2016.10.042 27863252
Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell. 2016;167(5):1415–e2919. 10.1016/j.cell.2016.10.04227863252
24. Graham SE Clarke SL Wu KH The power of genetic diversity in genome-wide association studies of lipids Nature 2021 600 7890 675 9 10.1038/s41586-021-04064-3 34887591
Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature. 2021;600(7890):675–9. 10.1038/s41586-021-04064-334887591
25. Ference BA Kastelein JJP Ray KK Association of Triglyceride-Lowering LPL variants and LDL-C-Lowering LDLR variants with risk of Coronary Heart Disease JAMA 2019 321 4 364 73 10.1001/jama.2018.20045 30694319
Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364–73. 10.1001/jama.2018.2004530694319
26. Ference BA Ray KK Catapano AL Mendelian randomization study of ACLY and Cardiovascular Disease N Engl J Med 2019 380 11 1033 42 10.1056/NEJMoa1806747 30865797
Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380(11):1033–42. 10.1056/NEJMoa180674730865797
27. Burgess S Dudbridge F Thompson SG Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods Stat Med 2016 35 11 1880 906 10.1002/sim.6835 26661904
Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880–906. 10.1002/sim.683526661904
28. Bowden J Del Greco MF Minelli C Davey Smith G Sheehan NA Thompson JR Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic Int J Epidemiol 2016 45 6 1961 74 10.1093/ije/dyw220 27616674
Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int J Epidemiol. 2016;45(6):1961–74. 10.1093/ije/dyw22027616674
29. Staley JR Blackshaw J Kamat MA PhenoScanner: a database of human genotype-phenotype associations Bioinf (Oxford England) 2016 32 20 3207 9 10.1093/bioinformatics/btw373
Staley JR, Blackshaw J, Kamat MA, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinf (Oxford England). 2016;32(20):3207–9. 10.1093/bioinformatics/btw373
30. Kamat MA Blackshaw JA Young R PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations Bioinf (Oxford England) 2019 35 22 4851 3 10.1093/bioinformatics/btz469
Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinf (Oxford England). 2019;35(22):4851–3. 10.1093/bioinformatics/btz469
31. Nikpay M Goel A Won HH A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease Nat Genet 2015 47 10 1121 30 10.1038/ng.3396 26343387
Nikpay M, Goel A, Won HH, et al. A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease. Nat Genet. 2015;47(10):1121–30. 10.1038/ng.339626343387
32. Burgess S Butterworth A Thompson SG Mendelian randomization analysis with multiple genetic variants using summarized data Genet Epidemiol 2013 37 7 658 65 10.1002/gepi.21758 24114802
Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65. 10.1002/gepi.2175824114802
33. Bowden J Davey Smith G Haycock PC Burgess S Consistent estimation in Mendelian randomization with some Invalid instruments using a weighted median estimator Genet Epidemiol 2016 40 4 304 14 10.1002/gepi.21965 27061298
Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14. 10.1002/gepi.2196527061298
34. Bowden J Davey Smith G Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression Int J Epidemiol 2015 44 2 512 25 10.1093/ije/dyv080 26050253
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512–25. 10.1093/ije/dyv08026050253
35. Burgess S Thompson SG Interpreting findings from Mendelian randomization using the MR-Egger method Eur J Epidemiol 2017 32 5 377 89 10.1007/s10654-017-0255-x 28527048
Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol. 2017;32(5):377–89. 10.1007/s10654-017-0255-x28527048
36. Paternoster R Brame R Mazerolle P Piquero A Using the correct statistical test for Equality of Regression coefficients Criminology 1998 36 859 66 10.1111/j.1745-9125.1998.tb01268.x
Paternoster R, Brame R, Mazerolle P, Piquero A. Using the correct statistical test for equality of regression coefficients. Criminology. 1998;36:859–66. 10.1111/j.1745-9125.1998.tb01268.x
37. Zuber V Grinberg NF Gill D Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches Am J Hum Genet 2022 109 5 767 82 10.1016/j.ajhg.2022.04.001 35452592
Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109(5):767–82. 10.1016/j.ajhg.2022.04.00135452592
38. Watanabe K Taskesen E van Bochoven A Posthuma D Functional mapping and annotation of genetic associations with FUMA Nat Commun 2017 8 1 1826 10.1038/s41467-017-01261-5 29184056
Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8(1):1826. 10.1038/s41467-017-01261-529184056
39. Preiss D Tikkanen MJ Welsh P Lipid-modifying therapies and risk of pancreatitis: a meta-analysis JAMA 2012 308 8 804 11 10.1001/jama.2012.8439 22910758
Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012;308(8):804–11. 10.1001/jama.2012.843922910758
40. Tazuma S Kajiyama G Mizuno T A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy J Clin Gastroenterol 1998 26 4 287 91 10.1097/00004836-199806000-00015 9649013
Tazuma S, Kajiyama G, Mizuno T, et al. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy. J Clin Gastroenterol. 1998;26(4):287–91. 10.1097/00004836-199806000-000159649013
41. Logan GM Duane WC Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation Gastroenterology 1990 98 6 1572 6 10.1016/0016-5085(90)91092-k 2338194
Logan GM, Duane WC. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology. 1990;98(6):1572–6. 10.1016/0016-5085(90)91092-k2338194
42. Binnington B Nguyen L Kamani M Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling Glycobiology 2016 26 2 166 80 10.1093/glycob/cwv084 26405105
Binnington B, Nguyen L, Kamani M, et al. Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling. Glycobiology. 2016;26(2):166–80. 10.1093/glycob/cwv08426405105
43. Lee BJ Kim JS Kim BK Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice J Gastroenterol Hepatol 2010 25 6 1105 10 10.1111/j.1440-1746.2010.06246.x 20594226
Lee BJ, Kim JS, Kim BK, et al. Effects of sphingolipid synthesis inhibition on cholesterol gallstone formation in C57BL/6J mice. J Gastroenterol Hepatol. 2010;25(6):1105–10. 10.1111/j.1440-1746.2010.06246.x20594226
44. Yang G Schooling CM Statins Type 2 diabetes, and body Mass Index: a univariable and multivariable Mendelian randomization study J Clin Endocrinol Metab 2023 108 2 385 96 10.1210/clinem/dgac562 36184662
Yang G, Schooling CM, Statins. Type 2 diabetes, and body mass index: a univariable and multivariable Mendelian randomization study. J Clin Endocrinol Metab. 2023;108(2):385–96. 10.1210/clinem/dgac56236184662
45. Lotta LA Sharp SJ Burgess S Association between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and risk of type 2 diabetes: a Meta-analysis JAMA 2016 316 13 1383 91 10.1001/jama.2016.14568 27701660
Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383–91. 10.1001/jama.2016.1456827701660
46. Shaffer EA Gallstone disease: epidemiology of gallbladder stone disease. Best practice & research Clin Gastroenterol 2006 20 6 981 96 10.1016/j.bpg.2006.05.004
Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best practice & research. Clin Gastroenterol. 2006;20(6):981–96. 10.1016/j.bpg.2006.05.004
47. Schooling CM, Zhao JV, Au Yeung SL, Leung GM. Investigating pleiotropic effects of statins on ischemic heart disease in the UK Biobank using Mendelian randomisation. eLife. 2020;9. 10.7554/eLife.58567
48. Li S Schooling CM A phenome-wide association study of genetically mimicked statins BMC Med 2021 19 1 151 10.1186/s12916-021-02013-5 34187478
Li S, Schooling CM. A phenome-wide association study of genetically mimicked statins. BMC Med. 2021;19(1):151. 10.1186/s12916-021-02013-534187478
